{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=2&sponsor=Idorsia+Pharmaceuticals+Ltd.", "query": { "sponsor": "Idorsia Pharmaceuticals Ltd.", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 40, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=3&sponsor=Idorsia+Pharmaceuticals+Ltd.&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=1&sponsor=Idorsia+Pharmaceuticals+Ltd.&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-12T11:22:03.279Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03541174", "title": "A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Resistant Hypertension" ], "interventions": [ { "name": "Aprocitentan 12.5 mg", "type": "DRUG" }, { "name": "Aprocitentan 25 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Idorsia Pharmaceuticals Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 730, "start_date": "2018-06-18", "completion_date": "2022-04-25", "has_results": true, "last_update_posted_date": "2023-03-21", "last_synced_at": "2026-10-12T11:22:03.279Z", "location_count": 41, "location_summary": "Alexander City, Alabama • Inglewood, California • Lincoln, California + 37 more", "locations": [ { "city": "Alexander City", "state": "Alabama" }, { "city": "Inglewood", "state": "California" }, { "city": "Lincoln", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Northridge", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03541174" }, { "nct_id": "NCT03425539", "title": "Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Fabry Disease" ], "interventions": [ { "name": "Lucerastat", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Idorsia Pharmaceuticals Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 118, "start_date": "2018-06-21", "completion_date": "2021-09-02", "has_results": true, "last_update_posted_date": "2024-08-09", "last_synced_at": "2026-10-12T11:22:03.279Z", "location_count": 17, "location_summary": "Birmingham, Alabama • Irvine, California • Oakland, California + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Irvine", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03425539" }, { "nct_id": "NCT02841709", "title": "Efficacy and Safety of ACT-541468 in Elderly Subjects With Insomnia Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Insomnia Disorder" ], "interventions": [ { "name": "ACT-541468", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Idorsia Pharmaceuticals Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 58, "start_date": "2016-11-28", "completion_date": "2017-06-29", "has_results": true, "last_update_posted_date": "2020-04-24", "last_synced_at": "2026-10-12T11:22:03.279Z", "location_count": 5, "location_summary": "Brandon, Florida • Chicago, Illinois • Las Vegas, Nevada + 2 more", "locations": [ { "city": "Brandon", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "New York", "state": "New York" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02841709" }, { "nct_id": "NCT00458276", "title": "Study of the Efficacy and Safety of Tezosentan in Patients With Pre-operative Pulmonary Hypertension, Due to Left Heart Disease, Undergoing Open Heart Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Heart Diseases", "Hypertension, Pulmonary" ], "interventions": [ { "name": "tezosentan", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Idorsia Pharmaceuticals Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 274, "start_date": "2007-04", "completion_date": "2008-03", "has_results": false, "last_update_posted_date": "2018-07-09", "last_synced_at": "2026-10-12T11:22:03.279Z", "location_count": 9, "location_summary": "Stanford, California • New York, New York • Durham, North Carolina + 5 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00458276" }, { "nct_id": "NCT05422612", "title": "Department of Defense PTSD Adaptive Platform Trial - Master Protocol", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Post Traumatic Stress Disorder" ], "interventions": [ { "name": "Intervention A Fluoxetine Hydrochloride (HCl)", "type": "DRUG" }, { "name": "Intervention A Placebo", "type": "DRUG" }, { "name": "Intervention B Vilazodone Hydrochloride (HCl)", "type": "DRUG" }, { "name": "Intervention B Placebo", "type": "DRUG" }, { "name": "Intervention C Daridorexant", "type": "DRUG" }, { "name": "Intervention C Placebo", "type": "DRUG" }, { "name": "Intervention D SLS-002", "type": "DRUG" }, { "name": "Intervention D Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Global Coalition for Adaptive Research", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 800, "start_date": "2023-11-02", "completion_date": "2029-07", "has_results": false, "last_update_posted_date": "2026-06-30", "last_synced_at": "2026-10-12T11:22:03.279Z", "location_count": 9, "location_summary": "Miami, Florida • Atlanta, Georgia • Tripler AMC, Hawaii + 6 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Tripler AMC", "state": "Hawaii" }, { "city": "Fort Thomas", "state": "Kentucky" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05422612" }, { "nct_id": "NCT05597020", "title": "A Study to Find Out if Daridorexant is Safe and Efficacious in Patients With Insomnia and Comorbid Nocturia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Insomnia Disorder", "Nocturia" ], "interventions": [ { "name": "Daridorexant", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Idorsia Pharmaceuticals Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": null, "sex": "ALL", "summary": "55 Years and older" }, "enrollment_count": 60, "start_date": "2023-02-16", "completion_date": "2024-04-18", "has_results": true, "last_update_posted_date": "2025-04-18", "last_synced_at": "2026-10-12T11:22:03.279Z", "location_count": 5, "location_summary": "Miami Beach, Florida • Pompano Beach, Florida • Weston, Florida + 2 more", "locations": [ { "city": "Miami Beach", "state": "Florida" }, { "city": "Pompano Beach", "state": "Florida" }, { "city": "Weston", "state": "Florida" }, { "city": "Shreveport", "state": "Louisiana" }, { "city": "Cary", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05597020" }, { "nct_id": "NCT06393504", "title": "Database Study to Provide Information on Pregnancy and Infant Outcomes Among Women Exposed to QUVIVIQ (Daridorexant)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Insomnia Disorder" ], "interventions": [ { "name": "Daridorexant", "type": "DRUG" }, { "name": "Non-orexin receptor antagonist insomnia medication", "type": "DRUG" }, { "name": "No insomnia medication", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Idorsia Pharmaceuticals Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "50 Years", "sex": "FEMALE", "summary": "15 Years to 50 Years · Female only" }, "enrollment_count": 2095, "start_date": "2023-11-30", "completion_date": "2028-04", "has_results": false, "last_update_posted_date": "2025-08-19", "last_synced_at": "2026-10-12T11:22:03.279Z", "location_count": 1, "location_summary": "Wilmington, Delaware", "locations": [ { "city": "Wilmington", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT06393504" }, { "nct_id": "NCT03869320", "title": "A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of ACT-1004-1239 in Healthy Male Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "ACT-1004-1239", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "ACT-1004-1239 (Food-effect subpart)", "type": "DRUG" }, { "name": "Placebo (Food-effect subpart)", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Idorsia Pharmaceuticals Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 64, "start_date": "2019-03-25", "completion_date": "2019-07-11", "has_results": false, "last_update_posted_date": "2020-01-10", "last_synced_at": "2026-10-12T11:22:03.279Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03869320" }, { "nct_id": "NCT03585270", "title": "Clinical Research Study With Clazosentan to Evaluate Its Effects on Preventing Complications Due to the Narrowing of the Blood Vessels (Vasospasm) in the Brain, Caused by Bleeding Onto the Surface of the Brain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Aneurysmal Subarachnoid Hemorrhage" ], "interventions": [ { "name": "Clazosentan", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Idorsia Pharmaceuticals Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 409, "start_date": "2019-02-03", "completion_date": "2022-11-18", "has_results": true, "last_update_posted_date": "2024-01-10", "last_synced_at": "2026-10-12T11:22:03.279Z", "location_count": 16, "location_summary": "Stanford, California • Jacksonville, Florida • Chicago, Illinois + 11 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03585270" }, { "nct_id": "NCT01241214", "title": "Study of ACT-129968 in Adult Patients With Seasonal Allergic Rhinitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Seasonal Allergic Rhinitis" ], "interventions": [ { "name": "ACT-129968", "type": "DRUG" }, { "name": "Cetirizine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Idorsia Pharmaceuticals Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 579, "start_date": "2010-11", "completion_date": "2011-02", "has_results": false, "last_update_posted_date": "2019-05-15", "last_synced_at": "2026-10-12T11:22:03.279Z", "location_count": 7, "location_summary": "Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 1 more", "locations": [ { "city": "Austin", "state": "Texas" }, { "city": "Kerrville", "state": "Texas" }, { "city": "New Braunfels", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01241214" } ] }